Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for management of malignant pleural mesothelioma. Eur Respir J 2010;35: 479-495.
Pass HI, Carbone M. Current status of screening for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 2009;21:97-104.
Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-1616. (Pubitemid 37443528)
Iwahori K, Osaki T, Serada S, et al. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin. Lung Cancer 2008;62:45-54.
Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004;10:3937-3942. (Pubitemid 38812466)
Hollevoet K, Nackaerts K, Thimpont J, et al. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med 2010;181:620-625.
Roe OD, Creaney J, Lundgren S, et al. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. Lung Cancer 2008;61:235-243.
Creaney J, Olsen NJ, Brims F, et al. Serum mesothelin for early detection of the asbestos-induced cancer malignant mesothelioma. Cancer Epidemiol Biomarkers Prev 2010;19:2238-2246.
Gube M, Taeger D, Weber DG, et al. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos. Arch Toxicol In press.
Crump C, McIntosh MW, Urban N, et al. Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening. Cancer Epidemiol Biomarkers Prev 2000;9:1107-1111.
Skates SJ, Xu FJ, Yu YH, et al. Towards an optimal algorithm for ovarian-cancer screening with longitudinal tumor-markers. Cancer 1995;76:2004 -2010.
Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006;12:447-453. (Pubitemid 43166134)
Hollevoet K, Bernard D, De Geeter F, et al. Glomerular filtration rate is a confounder for determination of serum soluble mesothelin. Clin Chem 2009;55:1431-1433.
Weber DG, Johnen G, Taeger D, et al. Assessment of confounding factors affecting the tumor markers SMRP, CA125, and CYFRA21-1 in serum. Biomark Insights 2010;5:1-8.
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612.
Arendt M, Bauer HD, Blome H, et al. BK-Report 1/2007 Faserjahre. Sankt Augustin: Hauptverband der gewerblichen Berufsgenossenschafte, 2007.
Beyer HL, Geschwindt RD, Glover CL, et al. Mesomark: a potential test for malignant pleural mesothelioma. Clin Chem 2007;53:666-672. (Pubitemid 46580236)
Cristaudo A, Foddis R, Vivaldi A, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007;13:5076-5081. (Pubitemid 47502073)
Pass HI, Wali A, Tang N, et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008;85:265-272. (Pubitemid 350265805)
Amati M, Tomasetti M, Mariotti L, et al. Assessment of Biomarkers in asbestos-exposed workers as indicators of cancer risk. Mutat Res 2008; 655:52-58.
Rodriguez Portal JA, Rodriguez Becerra E, Rodriguez Rodriguez D, et al. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev 2009;18:646-650.
Park EK, Sandrini A, Yates DH, et al. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am J Respir Crit Care Med 2008;178:832-837.
Frierson HF, Moskaluk CA, Powell SM, et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol 2003;34:605-609. (Pubitemid 36750373)
Pepe MS, Etzioni R, Feng ZD, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-1061. (Pubitemid 32717537)
Creaney J, Robinson BW. Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin- related protein. Hematol Oncol Clin North Am 2005;19:1025-1040. (Pubitemid 41736040)
van Meerbeeck JP, Hillerdal G. Screening for mesothelioma- more harm than good? Am J Respir Crit Care Med 2008;178: 781-782.
